Benzodiazepine Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The benzodiazepine market is segmented by Products (Alprazolam, Diazepam, Lorazepam, Clonazepam), Application, Time of Action, and Geography.

Market Snapshot

Benzodiazepine Drugs Market Overview
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 2.4 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The benzodiazepine drugs market studied was anticipated to grow with a CAGR of 2.4%, during the forecast period. Benzodiazepines are a class of psychoactive drugs that are used to treat diseases like anxiety, insomnia, panic disorder, seizures, and alcohol withdrawal. Benzodiazepine drugs produce a calming effect by enhancing the effect of the neurotransmitter GABA (Gamma-Aminobutyric Acid). Benzodiazepines drugs are widely prescribed drugs across the world and are helpful to reduce anxiety disorders, seizures, inducing sleep and also used for sedation purposes prior to surgery or general anesthesia. Rise in the geriatric population, stressful lifestyle, daily habits are major factors for mental disturbance, which creates anxiety, maniac, and panic disorder conditions. The market for benzodiazepine drugs is expanding rapidly due to an increase in the prevalence of anxiety, seizures, insomnia, and a rise in concern for the prevention of stress and related conditions. Alprazolam segment is anticipated to expand growth due to its wide application in anxiety, panic disorders. However, misuse of benzodiazepine drugs may restrict the growth of this market.

Scope of the Report

Benzodiazepines is a class of psychoactive drugs that are used to treat diseases like anxiety, insomnia, panic disorder, seizures, and alcohol withdrawal. Benzodiazepine drugs are segmented by Products, Application, Time of Action and Geography.

By Product
By Application
Anxiety disorders
Alcohol Withdrawal
By Time of Action
Ultra-short Acting
Short Acting
Long Acting
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Anxiety Disorders Segment is Expected to Hold a Largest Market Share in the Benzodiazepine Drugs

Anxiety segment is anticipated to account for major share of the market during the forecast period.According to World Health Organization (WHO) estimated number of people living with anxiety disorders globally is 264 million in the year 2015 reflects a 14.9% increase since 2005, as a result of population growth and ageing and which is estimated to be 3.6%. Anxiety disorders are more common among females than males (4.6% in females compared to 2.6% in males at the global level).

In 2017, anxiety segment recorded more than 60% revenue share collectively with anti-depressants drugs and the boost in demand for anxiety therapeutics coupled with a rise in a number of companies investing to develop new anxiety drugs which drives the market revenue. Anxiety was a dominant segment of the benzodiazepines drug market globally in the year 2017 and expected to maintain same during the forecast period.


North America is Expected to Dominate the Market and Expected to do Same in the Forecast Period

North America is expected to hold a dominating position in the global benzodiazepine drugs market due to more FDA approvals in that region. Around 40 million adults in the United States are affected every year with anxiety disorders of which only 36.9% receive treatment according to Anxiety and Depression Association of America (ADAA). Increase in the development of mental health-care services and rising awareness towards anxiety disorders are responsible for the increase in the diagnosis of generalized anxiety disorder (GAD). Due to growth in geriatric population is increasing the anxiety diagnosis rates in Mexico, thus directly boosting the demand for physiotherapies such as Cognitive Behavior Therapy (CBT) and generalized anxiety disorder (GAD) medication.

Benzodiazepine Drugs Market Share

Competitive Landscape

The Benzodiazepine Drugs Market is moderately competitive and consists of several players. In terms of market share, more number of the players are currently dominating the market. Some of the companies which are currently dominating the market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bausch Health Companies, Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., H.Lundbeck A/S, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Apotex Inc., and Aurobindo Pharma among others.

Recent Developments

In September 2020, in Japan, Taisho Pharmaceutical Co., Ltd., initiated a phase II clinical trial to assess the efficacy of TS-142 in the treatment of insomnia. The trial is expected to complete in December 2021.

In February 2020, United States Food and Drug Administration provided approval to Merck for its Belsomra drug in the treatment of insomnia in patients with mild-to-moderate Alzheimer’s disease.

Table of Contents


    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rise in Prevalence of Anxiety disorders, Seizures and Insomnia Diseases

      2. 4.2.2 Rise in Adoption of Generic Drugs

    3. 4.3 Market Restraints

      1. 4.3.1 Misuse of Benzodiazepine Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Product

      1. 5.1.1 Alprazolam

      2. 5.1.2 Diazepam

      3. 5.1.3 Lorazepam

      4. 5.1.4 Clonazepam

    2. 5.2 By Application

      1. 5.2.1 Anxiety disorders

      2. 5.2.2 Seizures

      3. 5.2.3 Insomnia

      4. 5.2.4 Alcohol Withdrawal

    3. 5.3 By Time of Action

      1. 5.3.1 Ultra-short Acting

      2. 5.3.2 Short Acting

      3. 5.3.3 Long Acting

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Amneal Pharmaceuticals LLC

      2. 6.1.2 Apotex Inc.

      3. 6.1.3 Aurobindo Pharma

      4. 6.1.4 Bausch Health Companies, Inc.

      5. 6.1.5 F.Hoffmann-La Roche Ltd.

      6. 6.1.6 H.Lundbeck A/S

      7. 6.1.7 Mylan, N.V.

      8. 6.1.8 Pfizer Inc.

      9. 6.1.9 Sun Pharmaceutical Industries Ltd.

      10. 6.1.10 Teva Pharmaceutical Industries Ltd.

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Benzodiazepine Drugs Market market is studied from 2018 - 2026.

The Benzodiazepine Drugs Market is growing at a CAGR of 2.4% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Pfizer Inc., F. Hoffmann-La Roche Ltd, Bausch Health Companies, Inc, Mylan N.V., Teva Pharmaceutical Industries Ltd are the major companies operating in Benzodiazepine Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!